Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SLV-154

Phase 1Small molecule

SSolve Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell Cancer of Head and Neck (SCCHN)Recruiting

Squamous Cell Cancer of Head and Neck (SCCHN)Phase 1

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Squamous Cell Cancer of Head and Neck (SCCHN)

NCT06771219

Clinical

Trials by Indication[1]

Squamous Cell Cancer of Head and Neck (SCCHN)1 trial

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors

Recruiting·SSolve Therapeutics·Phase 1·NCT06771219·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SLV-154. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SLV-154 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SLV-154. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Solve Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSolve Therapeutics

Related News